Get all your news in one place.
100's of premium titles.
One app.
Start reading
Benzinga
Benzinga
Business
Vandana Singh

Regeneron's Gene Therapy Shows Significant Gains In Genetic Hearing Loss

Tarrytown,,Ny,-,March,21,,2020,-,This,Week,Regeneron

On Sunday, Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) unveiled updated data from its investigational gene therapy DB-OTO for profound genetic hearing loss caused by variants of the otoferlin (OTOF) gene.

The New England Journal of Medicine published the report. The annual American Academy of Otolaryngology-Head and Neck Surgery meeting presented the data.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.